ProQR Therapeutics is a clinical-stage biotechnology company developing RNA editing therapeutics based on its proprietary Axiomer platform, which uses endogenous ADAR enzymes to make precise, single-nucleotide edits in RNA via editing oligonucleotides without permanently altering DNA. The company targets serious diseases with significant unmet medical need and strong human genetic evidence, including cholestatic diseases, Rett syndrome, metabolic dysfunction-associated steatohepatitis, and cardiovascular disorders, with lead program AX-0810 in Phase 1 clinical trials and additional programs in preclinical and development stages. ProQR generates revenue through a dual strategy of developing priority programs internally while monetizing the broader Axiomer platform through strategic partnerships, exemplified by an expanded global licensing and research collaboration with Eli Lilly that provides upfront payments, potential milestone payments, and royalties.